A guide to taming a toxin - Recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

FEBS Journal

Volumn 278, Issue 23, 2011, Pages 4683-4700

  Weldon, John E ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

antibody conjugates; cancer therapy; intracellular trafficking; moxetumomab pasudotox; Pseudomonas exotoxin A; recombinant immunotoxins

Indexed keywords

ANTINEOPLASTIC AGENT; CAT 3888; CAT 8015; CINTREDEKIN BESUDOTOX; CISPLATIN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOTOXIN; IMMUNOTOXIN BL22; IMMUNOTOXIN LMB2; IMMUNOTOXIN MR1 1; IMMUNOTOXIN SS1P; MOXETUMOMAB PASUDOTOX; NALMEFENE; PEMETREXED; PSEUDOMONAS EXOTOXIN BASED RECOMBINANT IMMUNOTOXIN; RECOMBINANT PROTEIN; TP 38; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY PRODUCTION; B CELL LYMPHOMA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOSOL; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG TARGETING; DRUG TOXICITY; ENDOPLASMIC RETICULUM; ENDOSOME; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; INTOXICATION; LUNG CANCER; MESOTHELIOMA; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN ENGINEERING; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; T CELL LYMPHOMA; TOXIN STRUCTURE;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; EXOTOXINS; HUMANS; IMMUNOTOXINS; NEOPLASMS; PROTEIN CONFORMATION; PSEUDOMONAS AERUGINOSA; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

PSEUDOMONAS AERUGINOSA; PSEUDOMONAS EXOTOXIN;

EID: 81555214408     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08182.x     Document Type: Review

References (163)

1. Barlow Pugh M, et al. (2006) Stedman's Medical Dictionary (, Barlow Pugh M, et al, eds), Lippincott Williams & Wilkins, Baltimore, MD.
2. Gill DM, (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46, 86-94. (Pubitemid 12101491)
3. Murray PR, Rosenthal KS, &, Pfaller MA, eds (2009) Medical Microbiology, 6th edn. Elsevier, Inc., Philadelphia, PA.
4. Naglich JG, Metherall JE, Russell DW, &, Eidels L, (1992) Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69, 1051-1061.
5. Manoukian G, &, Hagemeister F, (2009) Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9, 1445-1451.
6. Kadin ME, &, Vonderheid EC, (2010) Targeted therapies: Denileukin diftitox-a step towards a 'magic bullet' for CTCL. Nat Rev Clin Oncol 7, 430-432.
7. Jørgensen R, Purdy AE, Fieldhouse RJ, Kimber MS, Bartlett DH, &, Merrill AR, (2008) Cholix toxin, a novel ADP-ribosylating factor from Vibrio cholerae. J Biol Chem 283, 10671-10678.
8. Sarnovsky R, Tendler T, Makowski M, Kiley M, Antignani A, Traini R, Zhang J, Hassan R, &, FitzGerald DJ, (2010) Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin. Cancer Immunol Immunother 59, 737-746.
9. Driscoll JA, Brody SL, &, Kollef MH, (2007) The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67, 351-368. (Pubitemid 46425550)
10. Liu PV, (1966) The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo. J Infect Dis 116, 481-489.
11. Iglewski BH, (1996) Pseudomonas. In Medical Microbiology, 4th edn (, Baron S, ed), 27. University of Texas Medical Branch at Galveston, Galveston, TX.
12. Allured VS, Collier RJ, Carroll SF, &, McKay DB, (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-angstrom resolution. Proc Natl Acad Sci USA 83, 1320-1324. (Pubitemid 16016120)
13. Humphrey W, Dalke A, &, Schulten K, (1996) VMD-visual molecular dynamics. J Mol Graph 14, 33-38.
14. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, &, Saelinger CB, (1992) The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 267, 12420-12423.
15. Pastrana DV, Hanson AJ, Knisely J, Bu G, &, Fitzgerald DJ, (2005) LRP 1 B functions as a receptor for Pseudomonas exotoxin. Biochim Biophys Acta 1741, 234-239. (Pubitemid 41338668)
16. Hwang J, Fitzgerald DJ, Adhya S, &, Pastan I, (1987) Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48, 129-136.
17. Siegall CB, Chaudhary VK, FitzGerald DJ, &, Pastan I, (1989) Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem 264, 14256-14261. (Pubitemid 19214253)
18. Kihara A, &, Pastan I, (1994) Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha. Bioconjug Chem 5, 532-538.
19. FitzGerald DJ, Padmanabhan R, Pastan I, &, Willingham MC, (1983) Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 32, 607-617.
20. FitzGerald DJ, Trowbridge IS, Pastan I, &, Willingham MC, (1983) Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. Proc Natl Acad Sci USA 80, 4134-4138. (Pubitemid 13072782)
21. Chaudhary VK, FitzGerald DJ, Adhya S, &, Pastan I, (1987) Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci USA 84, 4538-4542.
22. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, &, Pastan I, (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339, 394-397. (Pubitemid 19144230)
23. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, &, Whitlow M, (1988) Single-chain antigen-binding proteins. Science 242, 423-426 (Erratum: 1989, Science 244, 409).
24. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85, 5879-5883.
25. Brinkmann U, Reiter Y, Jung SH, Lee B, &, Pastan I, (1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 90, 7538-7542. (Pubitemid 23249985)
26. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, &, Pastan I, (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 33, 5451-5459. (Pubitemid 24162980)
27. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, &, Pastan I, (1994) Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng 7, 697-704. (Pubitemid 24150079)
28. Pastan I, Beers R, &, Bera TK, (2004) Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 248, 503-518.
29. Kreitman RJ, Siegall CB, Chaudhary VK, FitzGerald DJ, &, Pastan I, (1992) Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin. Bioconjug Chem 3, 63-68.
30. Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE II, Pastan I, &, Bigner DD, (2010) Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer 129, 111-121.
31. Berger EA, &, Pastan I, (2010) Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 6, e1000803.
32. Kennedy PE, Bera TK, Wang QC, Gallo M, Wagner W, Lewis MG, Berger EA, &, Pastan I, (2006) Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J Leukoc Biol 2006, 80.
33. Onda M, Olafsen T, Tsutsumi Y, Bruland OS, &, Pastan I, (2001) Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J Immunother 24, 144-150. (Pubitemid 32184318)
34. Onda M, Bruland ØS, &, Pastan I, (2005) TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma. Clin Orthop Relat Res 430, 142-148. (Pubitemid 40096144)
35. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, &, Pastan I, (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23, 6719-6729. (Pubitemid 46190267)
36. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, &, Pastan I, (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27, 2983-2990.
37. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, &, Pastan I, (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16, 1894-1903.
38. Salvatore G, Beers R, Margulies I, Kreitman RJ, &, Pastan I, (2002) Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 8, 995-1002. (Pubitemid 35177347)
39. Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA, &, Pastan I, (2009) CAT-8015: a second-generation Pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 15, 832-839.
40. Kreitman RJ, (2009) Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des 15, 2652-2664.
41. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, &, Pastan I, (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin- expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13, 5144-5149. (Pubitemid 47502082)
42. Kreitman RJ, Hassan R, Fitzgerald DJ, &, Pastan I, (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15, 5274-5279.
43. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, &, Pastan I, (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18, 1622-1636. (Pubitemid 30220540)
44. Wolf P, &, Elsässer-Beile U, (2009) Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 299, 161-176.
45. Shapira A, &, Benhar I, (2010) Toxin-based therapeutic approaches. Toxins 2, 2519-2583.
46. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, Fitzgerald DJ, &, Pastan I, (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113, 3792-3800.
47. Leppla SH, Martin OC, &, Muehl LA, (1978) The exotoxin P. aeruginosa: a proenzyme having an unusual mode of activation. Biochem Biophys Res Commun 81, 532-538. (Pubitemid 8364912)
48. Wedekind JE, Trame CB, Dorywalska M, Koehl P, Raschke TM, McKee M, FitzGerald D, Collier RJ, &, McKay DB, (2001) Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. J Mol Biol 314, 823-837. (Pubitemid 34087850)
49. Ogata M, Chaudhary VK, Pastan I, &, FitzGerald DJ, (1990) Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 265, 20678-20685. (Pubitemid 120014061)
50. Ogata M, Fryling CM, Pastan I, &, FitzGerald DJ, (1992) Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 267, 25396-25401.
51. Fryling C, Ogata M, &, FitzGerald D, (1992) Characterization of a cellular protease that cleaves Pseudomonas exotoxin. Infect Immun 60, 497-502.
52. Moehring JM, Inocencio NM, Robertson BJ, &, Moehring TJ, (1993) Expression of mouse furin in a Chinese hamster cell resistant to Pseudomonas exotoxin A and viruses complements the genetic lesion. J Biol Chem 268, 2590-2594. (Pubitemid 23057883)
53. Chiron MF, Fryling CM, &, FitzGerald DJ, (1994) Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem 269, 18167-18176. (Pubitemid 24206217)
54. Inocencio NM, Moehring JM, &, Moehring TJ, (1994) Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J Biol Chem 269, 31831-31835. (Pubitemid 24379555)
55. Gordon VM, Klimpel KR, Arora N, Henderson MA, &, Leppla SH, (1995) Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 63, 82-87.
56. Gu M, Gordon VM, Fitzgerald DJ, &, Leppla SH, (1996) Furin regulates both the activation of Pseudomonas exotoxin A and the quantity of the toxin receptor expressed on target cells. Infect Immun 64, 524-527. (Pubitemid 26032824)
57. Sarac MS, Cameron A, &, Lindberg I, (2002) The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 70, 7136-7139. (Pubitemid 35387951)
58. Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, Wei G, Bottini M, Rega MF, Parent A, Desjardins R, et al. (2007) Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 282, 20847-20853. (Pubitemid 47099910)
59. Ornatowski W, Poschet JF, Perkett E, Taylor-Cousar JL, &, Deretic V, (2007) Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J Clin Invest 117, 3489-3497. (Pubitemid 350097004)
60. Thomas G, (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3, 753-766.
61. McKee ML, &, FitzGerald DJ, (1999) Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry 38, 16507-16513.
62. Chaiswing L, &, Oberley TD, (2010) Extracellular/microenvironmental redox state. Antioxid Redox Signal 13, 449-465.
63. Appenzeller-Herzog C, &, Ellgaard L, (2008) The human PDI family: versatility packed into a single fold. Biochim Biophys Acta 1783, 535-548.
64. Turano C, Coppari S, Altieri F, &, Ferraro A, (2002) Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol 193, 154-163.
65. Kimura T, Horibe T, Sakamoto C, Shitara Y, Fujiwara F, Komiya T, Yamamoto A, Hayano T, Takahashi N, &, Kikuchi M, (2008) Evidence for mitochondrial localization of P5, a member of the protein disulphide isomerase family. J Biochem 144, 187-196.
66. Orlandi PA, (1997) Protein-disulfide isomerase-mediated reduction of the A subunit of cholera toxin in a human intestinal cell line. J Biol Chem 272, 4591-4599. (Pubitemid 27078541)
67. Majoul I, Ferrari D, &, Söling HD, (1997) Reduction of protein disulfide bonds in an oxidizing environment. The disulfide bridge of cholera toxin A-subunit is reduced in the endoplasmic reticulum. FEBS Lett 401, 104-108. (Pubitemid 27056096)
68. Tsai B, Rodighiero C, Lencer WI, &, Rapoport TA, (2001) Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin. Cell 104, 937-948. (Pubitemid 32289285)
69. Spooner RA, Watson PD, Marsden CJ, Smith DC, Moore KA, Cook JP, Lord JM, &, Roberts LM, (2004) Protein disulphide-isomerase reduces ricin to its A and B chains in the endoplasmic reticulum. Biochem J 383, 285-293. (Pubitemid 39446689)
70. Moore P, Bernardi KM, &, Tsai B, (2010) The Ero1alpha-PDI redox cycle regulates retro-translocation of cholera toxin. Mol Biol Cell 21, 1305-1313.
71. Watson P, &, Spooner RA, (2010) Toxin entry and trafficking in mammalian cells. Adv Drug Deliv Rev 58, 1581-1596. (Pubitemid 44827431)
72. Beaumelle B, Bensammar L, &, Bienvenüe A, (1992) Selective translocation of the A chain of diphtheria toxin across the membrane of purified endosomes. J Biol Chem 267, 11525-11531.
73. Chaudhary VK, Jinno Y, FitzGerald D, &, Pastan I, (1990) Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 87, 308-312.
74. Munro S, &, Pelham HR, (1987) A C-terminal signal prevents secretion of luminal ER proteins. Cell 48, 899-907.
75. Lewis MJ, &, Pelham HR, (1990) A human homologue of the yeast HDEL receptor. Nature 348, 162-163.
76. Capitani M, &, Sallese M, (2009) The KDEL receptor: new functions for an old protein. FEBS Lett 583, 3863-3871.
77. Tang BL, Wong SH, Qi XL, Low SH, &, Hong W, (1993) Molecular cloning, characterization, subcellular localization and dynamics of p23, the mammalian KDEL receptor. J Cell Biol 120, 325-338. (Pubitemid 23040073)
78. Griffiths G, Ericsson M, Krijnse-Locker J, Nilsson T, Goud B, Soling HD, Tang BL, Wong SH, &, Hong W, (1994) Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate compartment in mammalian cells. J Cell Biol 127, 1557-1574. (Pubitemid 24380896)
79. Raykhel I, Alanen H, Salo K, Jurvansuu J, Nguyen VD, Latva-Ranta M, &, Ruddock L, (2007) A molecular specificity code for the three mammalian KDEL receptors. J Cell Biol 179, 1193-1204. (Pubitemid 350277738)
80. Jackson ME, Simpson JC, Girod A, Pepperkok R, Roberts LM, &, Lord JM, (1999) The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. J Cell Sci 112, 467-475. (Pubitemid 29106194)
81. Kreitman RJ, &, Pastan I, (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307, 29-37.
82. Hessler JL, &, Kreitman RJ, (1997) An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36, 14577-14582. (Pubitemid 27509950)
83. Seetharam S, Chaudhary VK, FitzGerald D, &, Pastan I, (1991) Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem 266, 17376-17381. (Pubitemid 21907949)
84. Smith DC, Spooner RA, Watson PD, Murray JL, Hodge TW, Amessou M, Johannes L, Lord JM, &, Roberts LM, (2006) Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum. Traffic 7, 379-393. (Pubitemid 43372748)
85. Mallard F, Antony C, Tenza D, Salamero J, Goud B, &, Johannes L, (1998) Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of shiga toxin B-fragment transport. J Cell Biol 143, 973-990. (Pubitemid 28547397)
86. Girod A, Storrie B, Simpson JC, Johannes L, Goud B, Roberts LM, Lord JM, Nilsson T, &, Pepperkok R, (1999) Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nat Cell Biol 1, 423-430. (Pubitemid 129502809)
87. Méré J, Morlon-Guyot J, Bonhoure A, Chiche L, &, Beaumelle B, (2005) Acid-triggered membrane insertion of Pseudomonas exotoxin A involves an original mechanism based on pH-regulated tryptophan exposure. J Biol Chem 280, 21194-21201. (Pubitemid 40805681)
88. Koopmann JO, Albring J, Hüter E, Bulbuc N, Spee P, Neefjes J, Hämmerling GJ, &, Momburg F, (2000) Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 13, 117-127.
89. Wirth A, Jung M, Bies C, Frien M, Tyedmers J, Zimmermann R, &, Wagner R, (2003) The Sec61p complex is a dynamic precursor activated channel. Mol Cell 12, 261-268. (Pubitemid 36945050)
90. Willer M, Forte GM, &, Stirling CJ, (2008) Sec61p is required for ERAD-L: genetic dissection of the translocation and ERAD-L functions of Sec61p using novel derivatives of CPY. J Biol Chem 283, 33883-33888.
91. Hazes B, &, Read RJ, (1997) Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36, 11051-11054. (Pubitemid 27398423)
92. Lord JM, Roberts LM, &, Lencer WI, (2005) Entry of protein toxins into mammalian cells by crossing the endoplasmic reticulum membrane: co-opting basic mechanisms of endoplasmic reticulum-associated degradation. Curr Top Microbiol Immunol 300, 149-168. (Pubitemid 43057940)
93. London E, &, Luongo CL, (1989) Domain-specific bias in arginine/lysine usage by protein toxins. Biochem Biophys Res Commun 160, 333-339. (Pubitemid 19116501)
94. Hershko A, &, Ciechanover A, (1998) The ubiquitin system. Annu Rev Biochem 67, 425-479. (Pubitemid 28411135)
95. Deeks ED, Cook JP, Day PJ, Smith DC, Roberts LM, &, Lord JM, (2002) The low lysine content of ricin A chain reduces the risk of proteolytic degradation after translocation from the endoplasmic reticulum to the cytosol. Biochemistry 41, 3405-3413. (Pubitemid 34214039)
96. Merrick WC, &, Nyborg J, (2000) Protein bioynthesis elongation cycle. In Translational Control of Gene Expression (, Sonenberg N, Hershey JWB, &, Mathews MB, eds), pp. 89-126. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
97. Liu S, Wiggins JF, Sreenath T, Kulkarni AB, Ward JM, &, Leppla SH, (2006) Dph3, a small protein required for diphthamide biosynthesis, is essential in mouse development. Mol Cell Biol 26, 3835-3841. (Pubitemid 43726400)
98. Webb TR, Cross SH, McKie L, Edgar R, Vizor L, Harrison J, Peters J, &, Jackson IJ, (2008) Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development. J Cell Sci 121, 3140-3145.
99. De Vendittis E, Amatruda MR, Raimo G, &, Bocchini V, (1997) Heterologous expression in Escherichia coli of the gene encoding an archaeal thermoacidophilic elongation factor 2. Properties of the recombinant protein. Biochimie 79, 303-308. (Pubitemid 27336287)
100. Foley BT, Moehring JM, &, Moehring TJ, (1992) A mutation in codon 717 of the CHO-K1 elongation factor 2 gene prevents the first step in the biosynthesis of diphthamide. Somat Cell Mol Genet 18, 227-231.
101. Foley BT, Moehring JM, &, Moehring TJ, (1995) Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analyses. J Biol Chem 270, 23218-23225.
102. Kimata Y, Harashima S, &, Kohno K, (1993) Expression of non-ADP-ribosylatable, diphtheria toxin-resistant elongation factor 2 in Saccharomyces cerevisiae. Biochem Biophys Res Commun 191, 1145-1151. (Pubitemid 23231609)
103. Phan LD, Perentesis JP, &, Bodley JW, (1993) Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J Biol Chem 268, 8665-8668. (Pubitemid 23118651)
104. Kimata Y, &, Kohno K, (1994) Elongation factor 2 mutants deficient in diphthamide formation show temperature-sensitive cell growth. J Biol Chem 269, 13497-13501. (Pubitemid 24206125)
105. Liu S, Milne GT, Kuremsky JG, Fink GR, &, Leppla SH, (2004) Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2. Mol Cell Biol 24, 9487-9497. (Pubitemid 39391685)
106. Ivankovic M, Rubelj I, Matulic M, Reich E, &, Brdar B, (2006) Site-specific mutagenesis of the histidine precursor of diphthamide in the human elongation factor-2 gene confers resistance to diphtheria toxin. Mutat Res 609, 34-42. (Pubitemid 44311619)
107. Roy V, Ghani K, &, Caruso M, (2010) A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin. PLoS ONE 5, e15753.
108. Gupta PK, Liu S, Batavia MP, &, Leppla SH, (2008) The diphthamide modification on elongation factor-2 renders mammalian cells resistant to ricin. Cell Microbiol 10, 1687-1694. (Pubitemid 352006150)
109. Ortiz PA, Ulloque R, Kihara GK, Zheng H, &, Kinzy TG, (2006) Translation elongation factor 2 anticodon mimicry domain mutants affect fidelity and diphtheria toxin resistance. J Biol Chem 281, 32639-32648. (Pubitemid 46036819)
110. Iglewski BH, &, Kabat D, (1975) NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin. Proc Natl Acad Sci USA 72, 2284-2288.
111. Van Ness BG, Howard JB, &, Bodley JW, (1980) ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and its hydrolysis products. J Biol Chem 255, 10710-10716.
112. Wilson BA, &, Collier RJ, (1992) Diphtheria toxin and Pseudomonas aeruginosa exotoxin A: active-site structure and enzymic mechanism. Curr Top Microbiol Immunol 175, 27-41.
113. Beattie BK, Prentice GA, &, Merrill AR, (1996) Investigation into the catalytic role for the tryptophan residues within domain III of Pseudomonas aeruginosa exotoxin A. Biochemistry 35, 15134-15142. (Pubitemid 26408844)
114. Armstrong S, Yates SP, &, Merrill AR, (2002) Insight into the catalytic mechanism of Pseudomonas aeruginosa exotoxin A. Studies of toxin interaction with eukaryotic elongation factor-2. J Biol Chem 277, 46669-46675. (Pubitemid 35417668)
115. Armstrong S, &, Merrill AR, (2004) Toward the elucidation of the catalytic mechanism of the mono-ADP-ribosyltransferase activity of Pseudomonas aeruginosa exotoxin A. Biochemistry 43, 183-194. (Pubitemid 38055954)
116. Jørgensen R, Merrill AR, Yates SP, Marquez VE, Schwan AL, Boesen T, &, Andersen GR, (2005) Exotoxin A-eEF2 complex structure indicates ADP ribosylation by ribosome mimicry. Nature 436, 979-984. (Pubitemid 41191675)
117. Jørgensen R, Wang Y, Visschedyk D, &, Merrill AR, (2008) The nature and character of the transition state for the ADP-ribosyltransferase reaction. EMBO Rep 9, 802-809.
118. Jørgensen R, Yates SP, Teal DJ, Nilsson J, Prentice GA, Merrill AR, &, Andersen GR, (2004) Crystal structure of ADP-ribosylated ribosomal translocase from Saccharomyces cerevisiae. J Biol Chem 279, 45919-45925. (Pubitemid 39491584)
119. Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, Peschel C, &, Licht T, (2004) Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 103, 2718-2726. (Pubitemid 38393030)
120. Sharma AK, &, FitzGerald D, (2010) Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis. Toxicon 56, 1025-1034.
121. Bogner C, Dechow T, Ringshausen I, Wagner M, Oelsner M, Lutzny G, Licht T, Peschel C, Pastan I, Kreitman RJ, et al. (2010) Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol 148, 99-109.
122. Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, &, Pastan I, (2010) Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 150, 352-358.
123. Du X, Youle RJ, FitzGerald DJ, &, Pastan I, (2010) Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol 30, 3444-3452.
124. Adams KW, &, Cooper GM, (2007) Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 282, 6192-6200. (Pubitemid 47100899)
125. Chaudhary VK, Xu YH, FitzGerald D, Adhya S, &, Pastan I, (1988) Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli. Proc Natl Acad Sci USA 85, 2939-2943.
126. Kasturi S, Kihara A, FitzGerald D, &, Pastan I, (1992) Alanine scanning mutagenesis identifies surface amino acids on domain II of Pseudomonas exotoxin required for cytotoxicity, proper folding, and secretion into periplasm. J Biol Chem 267, 23427-23433.
127. Voulhoux R, Taupiac MP, Czjzek M, Beaumelle B, &, Filloux A, (2000) Influence of deletions within domain II of exotoxin A on its extracellular secretion from Pseudomonas aeruginosa. J Bacteriol 182, 4051-4058. (Pubitemid 30436568)
128. Yamaizumi M, Mekada E, Uchida T, &, Okada Y, (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15, 245-250. (Pubitemid 9027527)
129. Kreitman RJ, &, Pastan I, (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 58, 968-975. (Pubitemid 28182466)
130. Fitzgerald D, (1996) Why toxins! Semin Cancer Biol 7, 87-95. (Pubitemid 26148451)
131. Bard F, Mazelin L, Péchoux-Longin C, Malhotra V, &, Jurdic P, (2003) Src regulates Golgi structure and KDEL receptor-dependent retrograde transport to the endoplasmic reticulum. J Biol Chem 278, 46601-46606. (Pubitemid 37452235)
132. Kreitman RJ, Tallman MS, Coutre S, Robak T, Wilson WH, Stetler-Stevenson M, Noel P, Fitzgerald DJ, Buzoinu M, Lechleider RJ, et al. (2010) A phase I study of Moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin, in relapsed/refractory hairy cell leukemia (HCL): updated results. American Society of Hematology (ASH) annual meeting abstract. 4-7 December 2010. Orlando, FL.
133. Wayne AS, Bhojwani D, Richards K, Stetler-Stevenson M, Silverman LB, Jeha S, Pui C, McDevitt J, Fitzgerald DJ, Kreitman RJ, et al. (2011) A phase I study of Moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin, in patients with pediatric acute lymphoblastic leukemia (ALL): updated results. American Society of Pediatric Hematology/Oncology (ASPHO) annual meeting abstract. 13-16 April 2011. Baltimore MD.
134. Powell DJ Jr, Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C, White DE, Mavroukakis S, Kreitman RJ, Rosenberg SA, et al. (2007) Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179, 4919-4928.
135. Hassan R, Sharon E, Schuler B, Mallory Y, Zhang J, Ling A, &, Pastan I, (2011) Anti-tumor activity of SS1P with pemetrexed and cisplatin for newly diagnosed patients with advanced pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. American Society of Clinical Oncology (ASCO) annual meeting abstract. 3-7 June 2011. Chicago, IL.
136. De Groot AS, &, Scott DW, (2007) Immunogenicity of protein therapeutics. Trends Immunol 28, 482-490. (Pubitemid 350087812)
137. Onda M, Beers R, Xiang L, Nagata S, Wang QC, &, Pastan I, (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105, 11311-11316.
138. Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, &, Pastan I, (2010) A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 33, 297-304.
139. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, &, Pastan I, (2011) A recombinant immunotoxin against B cell malignancies with no immunogenicity in mice by removal of B cell epitopes. Proc Natl Acad Sci USA 108, 5742-5747.
140. Jevsevar S, Kunstelj M, &, Porekar VG, (2010) PEGylation of therapeutic proteins. Biotechnol J 5, 113-128.
141. Benhar I, Wang QC, FitzGerald D, &, Pastan I, (1994) Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J Biol Chem 269, 13398-13404. (Pubitemid 24206112)
142. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, &, Pastan I, (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 97, 8548-8553. (Pubitemid 30639710)
143. Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang QC, Ho M, Beers R, et al. (2007) Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem 18, 773-784. (Pubitemid 47010797)
144. Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M, Mischak R, &, Spitler LE, (1990) Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J Biol Response Mod 9, 345-354. (Pubitemid 20248368)
145. Selvaggi K, Saria EA, Schwartz R, Vlock DR, Ackerman S, Wedel N, Kirkwood JM, Jones H, &, Ernstoff MS, (1993) Phase I/II study of murine monoclonal
146. Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, &, Pastan I, (2004) Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 10, 16-18. (Pubitemid 38114156)
147. Onda M, (2009) Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 10, 131-139.
148. Nagata S, &, Pastan I, (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61, 977-985.
149. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, et al. (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177, 8822-8834. (Pubitemid 44893849)
150. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, &, Harding FA, (2004) Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172, 6658-6665. (Pubitemid 38669101)
151. Mathew M, &, Verma RS, (2009) Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 100, 1359-1365.
152. Sitikov AS, Davydova EK, &, Ovchinnikov LP, (1984) Endogenous ADP-ribosylation of elongation factor 2 in polyribosome fraction of rabbit reticulocytes. FEBS Lett 176, 261-263. (Pubitemid 15203967)
153. Fendrick JL, Iglewski WJ, Moehring JM, &, Moehring TJ, (1992) Characterization of the endogenous ADP-ribosylation of wild-type and mutant elongation factor 2 in eukaryotic cells. Eur J Biochem 205, 25-31.
154. Bektaş M, Akçakaya H, Aroymak A, Nurten R, &, Bermek E, (2005) Effect of oxidative stress on in vivo ADP-ribosylation of eukaryotic elongation factor 2. Int J Biochem Cell Biol 37, 91-99. (Pubitemid 39286027)
155. Jäger D, Werdan K, &, Müller-Werdan U, (2011) Endogenous ADP-ribosylation of elongation factor-2 by interleukin-1β. Mol Cell Biochem 348, 125-128.
156. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, &, Zhang J, (2007) Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 13, 7166-7171. (Pubitemid 350276903)
157. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, Le N, Ho M, &, Pastan I, (2006) Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 12, 4695-4701. (Pubitemid 44297823)
158. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, &, Pastan I, (2010) A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res 70, 1082-1089.
159. Zhang Y, &, Pastan I, (2008) High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res 14, 7981-7986.
160. Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, &, Fitzgerald DJ, (2010) ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of Pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther 9, 2007-2015.
161. Kreitman RJ, Schneider WP, Queen C, Tsudo M, Fitzgerald DJ, Waldmann TA, &, Pastan I, (1992) Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor. J Immunol 149, 2810-2815.
162. Izidoro MA, Gouvea IE, Santos JA, Assis DM, Oliveira V, Judice WA, Juliano MA, Lindberg I, &, Juliano L, (2009) A study of human furin specificity using synthetic peptides derived from natural substrates, and effects of potassium ions. Arch Biochem Biophys 487, 105-114.
163. Du X, Beers R, Fitzgerald DJ, &, Pastan I, (2008) Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 68, 6300-6305.